The Effect of Fatty Liver On Hepatic Gene Expression and Protein Activity
Diseases and Conditions Researched
What is the purpose of this trial?Hypothesis 1. In patients with T2DM, as compared to nondiabetic controls, increased hepatic glucose production from hepatic gluconeogenesis is associated with increased transcription of gluconeogenic enzymes. Hypothesis 2. In patients with NAFLD, the accumulation of diacylglycerol (DAG) will be associated with increased activation of a novel protein kinase C isoform and hepatic insulin resistance. Hypothesis 3. Roux-en-Y gastric bypass (RYGB), but not gastric banding, will lead to rapid reductions in hepatic lipid content and improvements in hepatic insulin sensitivity. Hypothesis 4: Subjects with polymorphisms in ApoC3 who have increased liver content, will have accumulation of the fatty acid, DAG, and hepatic insulin resistance. Subjects with polymorphisms in PNPLA3, who have fatty liver, will have increased in other fat species than DAG and therefore have normal hepatic insulin action.
Click here for detailed participation information for this trial.
|Sponsor:||National Institutes of Health|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.